Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1 study of AZD6244 capsule safety, tolerability, and medication behavior in advanced solid malignancies
NL-OMON59501Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in Non-hematologic malignancy, sponsored by AstraZeneca. Primary endpoints: Safety, Tolerability and 1 more. Started Feb 2007; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON59501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59501.